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Abstract: Background: Drug adverse event (AE) signal detection using the Gamma 
Poisson Shrinker (GPS) is commonly applied in spontaneous reporting. AE signal 
detection using large observational health plan databases can expand medication safety 
surveillance. Methods: Using data from nine health plans, we conducted a pilot study to 
evaluate the implementation and findings of the GPS approach for two antifungal drugs, 
terbinafine and itraconazole, and two diabetes drugs, pioglitazone and rosiglitazone. We 
evaluated 1676 diagnosis codes grouped into 183 different clinical concepts and four levels 
of granularity. Several signaling thresholds were assessed. GPS results were compared to 
findings from a companion study using the identical analytic dataset but an alternative 
statistical method—the tree-based scan statistic (TreeScan). Results: We identified 71 
statistical signals across two signaling thresholds and two methods, including  
closely-related signals of overlapping diagnosis definitions. Initial review found that most 
signals represented known adverse drug reactions or confounding. About 31% of signals 
met the highest signaling threshold. Conclusions: The GPS method was successfully 
applied to observational health plan data in a distributed data environment as a drug safety 
data mining method. There was substantial concordance between the GPS and TreeScan 
approaches. Key method implementation decisions relate to defining exposures and 
outcomes and informed choice of signaling thresholds.  
Keywords: pharmacovigilance; drug safety surveillance; adverse events data mining; 
gamma Poisson shrinkage; tree-based scan statistic 
 
1. Introduction  
Quantitative identification of unspecified medical product-adverse event (AE) relationships—often 
referred to as signal detection—is integral to worldwide medical product safety surveillance. Gamma 
Poisson Shrinkage (GPS) is a disproportionality method commonly applied to spontaneous reporting 
systems for signal detection [1]. Implementation of signal detection methods using routinely collected 
electronic data can expand the scope and scale of pharmacovigilance. In contrast with spontaneous 
reporting systems, however, little experience has been gained in the implementation and interpretation 
of GPS with observational electronic health care claims and administrative data.  
Investigators have proposed a variety of AE signal detection methods for observational data, 
including disproportionality approaches [1–4], the tree-based scan statistic (TreeScan) [5,6] and  
others [7–10]. Disproportionality approaches, including GPS, Information Component (IC) and the 
proportional reporting ratio (PRR) all have been applied to observational data, typically in two 
fundamentally different ways. One approach has been to apply the methods as closely as possible to 
their implementation in spontaneous report datasets by using observational data to mimic spontaneous 
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reports of drug-event combinations [2,11], including the “spontaneous reporting system methods” of 
GPS, Information Component, PRR and reporting odds ratio (ROR) as implemented and evaluated in 
Schuemie et al. (2012). In one example, Curtis et al. (2008) identified exposure using the Medicare 
Current Beneficiary Survey (MCBS) and outcomes from a sample of medical claims linked to the 
MCBS. Monthly reports were created to mimic spontaneous reporting databases and analyzed as if 
they were spontaneous reports. Zorych (2011) used simulated and administrative claims data to 
evaluate disproportionality methods using three different approaches for creating the analytic 2 × 2 
table; none accounted for exposed or unexposed person time. Schuemie (2011) used simulated data to 
conduct a pilot implementation of several modifications of GPS, comparing person-level and 
exposure-day level approaches for calculating observed and expected counts, and specifically adjusting 
for protopathic bias [3].  
A second approach adapts these methods to try to better leverage the richness of longitudinal 
observational datasets. Noren et al. (2008; 2010) applied the Information Component Temporal Pattern 
Discovery (ICTPD) approach by comparing the observed count of a drug-outcome combination to an 
expected count based on general occurrences in the database, coupled with a self-controlled design 
element by comparing the Observed and Expected counts of an event after prescription to the 
Observed and Expected counts before prescription [4,12]. Schuemie et al. (2011) used simulated data 
to evaluate an alternative approach (Longitudinal GPS: LGPS) similar to our implementation here 
where rather than comparing to expected counts based on occurrence of events for patients taking 
other prescribed products he utilizes exposed and non-exposed time at risk to develop a richer 
denominator [13].  
Both implementation approaches have strengths and weaknesses. The LGPS method computes 
expected counts of medical events during drug exposure based on an aggregate of unexposed patient 
time in ever‐exposed and unexposed patients, potentially introducing confounding as unexposed 
patients may be less likely to have events related to the drug indication or underlying disease than the 
exposed population. For ICTPD, one of the two comparisons is of events occurring within a specific 
time after a dispensing of the drug of interest to all observations of that event after exposure to all 
other drugs but within the same at-risk period to give an Expected count. Inclusion of drugs associated 
with the outcome of interest will inflate the Expected count, and could lead to a reduced ICTPD score 
for the drug-event of interest; the inverse could occur with protective effects [14–16]. The GPS and 
ICTPD approaches and others differ in how a score is derived for the drug-outcome pairs, but also in 
terms of the test statistic, the choice of signaling threshold, as well as differences in implementation, 
some of which reflect the differences in the observational databases used (e.g., different terminological 
classifications of outcomes) [17]. 
More recently, Schuemie et al. (2012) and Ryan et al. (2012) published a comparison of multiple 
signal detection methods using longitudinal data across three countries [13,18]. The approaches are 
similar. Schuemie (2012) compared 10 methods using a set of positive and negative controls  
(drug-event pairs) for comparison. They reported positive results for most methods, including LGPS. 
Direct applicability of their results to routine open ended signal detection is hard to assess as they 
limited their assessment to a small set of known associations and their comparisons were based on area 
under the curve estimates on ROC curves where all sensitivity and specificity thresholds are 
considered equally important. In practice the tail ends of ROC curves may not be appropriate to 
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consider in assessing surveillance approach effectiveness; if there is great differential performance 
between methodological approaches in these tails of ROC curves a misleading impression of 
performance and erroneous comparisons between approaches can be made. Schuemie et al. (2012) 
focused on point estimates instead of the lower thresholds of confidence limits that are more 
commonly used in signal detection to protect against spurious findings [1]. Finally, focusing on point 
estimates creates the potential to favor methods that routinely over-estimate risk. 
Given that the GPS approach has shown promising results for use in longitudinal data [2,3,5,11,13], 
we furthered the prior work by applying GPS in a “real-world” environment not limited to specific 
associations but rather including non-prespecified drug-event pairs for evaluation. Such a real-world 
open ended discovery approach has not to our knowledge been taken with a GPS based method, 
although open ended discovery was done in Noren et al. (2010) for the ICTPD approach [12]. Our 
implementation closely mimicked the approach described in the U.S. Food and Drug Administration’s 
(FDA) Mini-Sentinel project for evaluation of non-prespecified AEs [19].  
We present a pilot study evaluating the implementation of GPS for drug-AE signal detection using 
routinely-collected electronic medical encounter data in a multi-site environment. We also compare the 
GPS results to findings from a TreeScan study that used identical input datasets.  
2. Methods  
2.1. Overview 
Signal detection using observational data requires three key specifications: (i) the analytic approach 
related to calculating exposures, identifying cases, defining comparators, and handling censoring; 
(ii) the statistical method used; and (iii) the signaling thresholds. Our implementation compared the 
rate of exposed outcomes with an expected count based on unexposed time. Therefore, the specific 
question was whether there is a statistical signal of excess risk of an outcome during exposed time as 
compared to unexposed time. In this paper we define a “signal” as a statistical association between a 
drug and a diagnosis within an exploratory framework without any requirement for verification of case 
status by medical record review or other confirmatory analysis. These “statistical signals” do not imply 
causality, but rather represent an association that meets pre-specified signaling thresholds that may 
warrant further investigation. Statistical signals identified using signal detection methods often can be 
explained by bias and confounding. We focused on signal detection implementation approaches using 
observational data, not prioritization and investigation of the signals identified. Such signal refinement 
requires additional methods and dedicated resources beyond the scope of this study [20]. 
2.2. Data and Study Population  
The study cohort consisted of approximately 3.4 million privately-insured health plan members 
enrolled between 1999 and 2003 distributed roughly equally across the nine plans in the HMO 
Research Network Center for Education and Research on Therapeutics: Harvard Pilgrim Health Care, 
Kaiser Permanente Georgia, Meyers Primary Care Institute, Group Health Cooperative, Lovelace 
Clinic Foundation, Kaiser Permanente Northern California, HealthPartners Research Foundation, 
Kaiser Permanente Colorado, and Kaiser Permanente Northwest. Each health plan maintains an 
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electronic database of member demographics, enrollment, outpatient pharmacy dispensing, and 
inpatient and outpatient encounters. These data have been used in several drug safety studies [21–27] 
and described in detail elsewhere [21,22,28]. 
Demographic information includes date of birth and sex. Enrollment consists of enrollment start 
and stop dates and a drug coverage indicator. Pharmacy dispensing data includes dispensing date, 
national drug code, units dispensed, and days supplied. Encounter information includes all diagnosis 
codes recorded during ambulatory and inpatient encounters.  
We employed a distributed data model [29–31] that enabled sites to share only summarized count 
information for aggregation and analysis. The study was approved by the Institutional Review Board at 
each site.  
2.3. Study Drugs 
We identified users of two antifungal drugs, terbinafine and itraconazole, and two diabetes drugs, 
pioglitazone and rosiglitazone. These products were selected because they have substantial exposure, 
well-characterized risks, and allow for within-indication comparisons. We noted established associations 
between terbinafine and itraconazole and risk of liver disease [32,33] and allergic reaction [34,35]. 
Itraconazole and both diabetes drugs carry black box warnings for congestive heart failure on the U.S. 
FDA approved product labeling . Each drug was analyzed separately, without consideration of prior or 
concurrent exposures.  
2.4. Diagnosis Definitions 
Starting with all ICD-9-CM diagnosis codes we removed diagnosis codes associated with 
conditions unlikely to be drug-associated acute AEs (e.g., neoplasms, pregnancy and perinatal 
conditions, congenital anomalies, injuries and poisoning, diabetes). The remaining 1676 diagnosis 
codes were grouped using the Multi-level Clinical Classifications Software (MLCCS) [36]. The 
MLCCS is a hierarchical system with four levels of clinical concepts denoted by four 2-digit 
identifiers. The top level MLCCS identifies 18 body systems, and each can have up to three sublevels, 
as represented by the 2nd, 3rd, and 4th 2-digit codes. Each diagnosis code belongs to one classification 
group at each level of the MLCCS system, creating a hierarchical tree structure, where related 
diagnoses are close to each other on the tree. The exclusion process resulted in 183 overlapping 
groupings of related clinical concepts that were evaluated as potential AEs. Table 1 illustrates the 
hierarchical tree structure. Analyses were done at all four levels of granularity separately. Since we 
created a single set of diagnoses across products, we expected to identify some “signals” that represent 
bias and confounding common to uncontrolled observational studies (e.g., pioglitazone patients will 
have a higher rate of diabetes related complications such as eye disorders). 
2.5. Contributed Person Time  
All individuals with a membership period with medical and drug coverage over 180 days 
contributed person time. Membership gaps of 60 days or less were bridged to create continuous 
membership periods. Contributed days began after a 180 day baseline period, and ended for that 
member at the first incident diagnosis of any clinical concept, the last day of enrollment, or the end of 
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the study period (December 31, 2003), whichever came first. Figure 1 illustrates how contributed time 
was parsed. The baseline period was used as to identify prior diagnoses; no exclusions were applied 
during baseline.  
Table 1. A small subset of the Multi-Level Clinical Classification Tree with International 
Classification of Diseases, Ninth Revision (ICD-9) codes associated with a specific level. 
07 Diseases of the Circulatory System  
07.01 Hypertension 
07.01.02 Hypertension with Complications and Secondary Hypertension  
07.01.02.01 Hypertensive Heart and/or Renal Disease (402.00–404.93) 
07.01.02.02 Other Hypertensive Complications (405.01–405.99,437.2) 
07.02 Diseases of The Heart 
07.02.01 Heart Valve Disorders 
07.02.01.02 Nonrheumatic Mitral Valve Disorders (424.0) 
07.02.01.03 Nonrheumatic Aortic Valve Disorders (424.1) 
07.02.01.04 Other Heart Valve Disorders (424.2, 424.3, 785.2, 785.3) 
07.02.02 Peri; Endo; and Myocarditis; Cardiomyopathy (Except that Caused by TB or STD) 
07.02.02.01 Cardiomyopathy (425.0–425.9) 
07.02.03 Acute Myocardial Infarction (410.0–410.92) 
07.02.04 Coronary Atherosclerosis and Other Heart Disease 
07.02.04.01 Angina Pectoris (413.0–413.9) 
07.02.04.02 Unstable Angina (Intermediate Coronary Syndrome) (411.1) 
07.02.04.03 Other Acute and Subacute Forms of Ischemic Heart Disease (411.0, 411.8–411.89) 
07.02.04.04 Coronary Atherosclerosis (414.05) 
07.02.04.05 Other Forms of Chronic Heart Disease (414.8, 414.9) 
07.02.04.00 Other (414.06) 
Figure 1. Contributed person time: member timelines. 
 
Rx
Membership Period
Baseline
Example 1. Illustrates contributed time for a member with unexposed  and exposed time, no outcomes
Diagnosis
Unexposed Exposed Unexposed
Rx
Baseline
Example 2. Illustrates contributed time for a member with an exposed outcome
Unexposed Exposed Censored
Diagnosis
Rx
Baseline
Example 3. Illustrates contributed time for a member with an unexposed outcome
Unexposed Censored
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2.6. Drug Exposure 
Contributed days were either exposed or unexposed person time. Treatment episodes (i.e., exposed 
person time) began the day after a drug dispensing and continued until the end of exposure based on 
days supplied. Consecutive dispensings were combined, and exposure gaps of six days or less were 
bridged to create continuous episodes. Unexposed person time was defined as all contributed days 
without exposure. For each product we calculated total exposed and unexposed person time. 
2.7. Outcomes 
We defined an incident outcome as the first observed diagnosis during contributed time that was not 
observed during baseline. Only the first incident outcome observed was counted and designated as 
exposed or unexposed; this restriction is necessary for the TreeScan analysis that adjusts for multiple 
testing and was applied here to enable comparison across methods.  
2.8. Calculation of Observed and Expected Counts 
Exposed outcomes are the number of incident outcomes observed during exposed days. The 
unadjusted expected count is the number of exposed days times the rate of incident outcomes during 
unexposed days, calculated as the number of unexposed outcomes divided by the number of unexposed 
days. Using indirect standardization, we adjusted expected counts for age, sex, and health plan.  
Following the distributed data model approach [29–31], each site executed analytic code provided 
by the study coordinating center. Analytic program output contained counts of exposed and unexposed 
days and outcomes by age (5-year strata) and sex; counts were transferred to the coordinating center 
for aggregation and analysis.  
2.9. Gamma Poisson Shrinker  
The GPS was proposed by DuMouchel [37,38] as a signal detection tool for large frequency tables 
with both observed (O) and expected (E) counts for each drug-outcome pair. It assumes the observed 
count of any drug-outcome pair follows the Poisson distribution. For spontaneous reports, there are no 
drug exposure denominator data, so the expected counts are calculated under the null assumption that 
each drug has the same proportion of diagnosis codes. That is, the expected counts are internally 
derived assuming the independence of drug and event reporting, and calculated as the product of two 
marginal frequencies of the drug-outcome pair and the total count of all observed events. For example, 
if seizures comprise 1% of all the diagnosis codes, over all drugs, and itraconazole has a total of  
800 diagnoses, then the expected number of seizures is eight for itraconazole.  
Unlike spontaneous reporting databases, population-based event monitoring using health plan data 
can calculate observed and expected counts based on observed exposure information and diagnoses 
observed during exposed and unexposed time. GPS can be directly adapted to such settings with the 
internally derived expected counts replaced by the expected counts constructed using the denominators.  
Details of the GPS algorithm have been extensively described [37–40]. Briefly, for each drug-outcome 
pair, the primary parameter of interest was the risk ratio. Rather than using the observed over expected 
(O/E), GPS uses the empirical Bayesian geometric mean (EBGM) posterior distribution of the risk 
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ratio and the surrounding confidence interval for each drug-outcome pair to identify statistical signals 
of excess risk. To prevent spurious false positives due to implausibly high risk ratios, GPS implements 
a Bayesian framework that “shrinks” O/E estimates towards a value which is close to the average O/E 
values for all drug-event pairs at each level of granularity. For these data, that average is about 1.5. 
GPS accomplishes this by use of an empirical Bayesian framework where the values of all O/E 
estimates are modeled as a mixture distribution. This so-called “prior distribution” is then combined 
with data on a specific drug–outcome pair to give a score: the EBGM. Further work would be needed 
to determine whether shrinkage towards an average value far from one is justified or represents an 
artificial attribute that might adversely impact performance of the GPS approach. We evaluated each 
level of the diagnosis tree separately.  
We used two signaling thresholds for GPS. The first is the lower bound of the 95% posterior 
probability interval of 1.5 or more (medium threshold). Since the average O/E for our population was 
close to 1.5, this threshold mimics an excess risk but is not adjusted for multiple testing. To informally 
adjust for multiple testing when applying data mining approaches to spontaneous reporting, the U.S. 
FDA uses the lower bound of the 90% posterior probability interval of EBGM of greater or equal to 
two as the signal threshold for their spontaneous reporting system [41]. We used this threshold as our 
most stringent signaling criteria.  
2.10. Comparison to Tree-Based Scan Statistic 
TreeScan is a signal detection method that simultaneously looks for excess risk in any of a large 
number of individual cells in a database and in groups of closely related cells, formally adjusting the  
p-values for the multiple testing inherent in the large number of overlapping diagnosis groups 
evaluated [6,42,43]. The paper by Kulldorff et al. (2012) details the TreeScan approach for drug safety 
surveillance [42]. In brief, a hierarchical classification tree is first constructed for the outcomes where 
related diagnoses are close to each other on the tree. Different cuts on the tree are then made, and it is 
evaluated whether the group of diagnoses on that branch of the tree has an excess risk of occurring 
among the drug users. In this way, the method evaluates both very specific outcome definitions such as 
Paralytic Ileus (a single leaf on the tree) as well as large groups of related outcomes such as Diseases 
of the Digestive System (one of the largest branches on the tree). The method formally adjusts for the 
multiple testing inherent in the hundreds or thousands of different cuts evaluated.  
For the comparison between GPS and TreeScan we used identical input datasets of age and sex 
stratified O and E counts for each MLCCS node separately for each drug. We conducted a post-hoc 
comparison of the GPS and TreeScan results focusing on differences in the number of signals 
identified overall and by signaling threshold. For this comparison we define two signaling thresholds 
for TreeScan: multiple testing adjusted p-values of <0.001 and 0.001 < p < 0.05. This comparison was 
made to help put the GPS results in context using a different statistical signaling method with the same 
input datasets. We used the product label, medical literature, and clinician input to informally 
categorize the signals as known, likely confounded, or previously unknown. Formal signal evaluation 
was beyond the scope of the project. 
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3. Results  
3.1. Terbinafine and Itraconazole 
Across all thresholds and nodes on the classification tree we identified 10 GPS terbinafine signals 
and four itraconazole signals (Table 2). One of the 10 terbinafine signals met the highest GPS 
threshold and five met the highest TreeScan threshold. Of the four itraconazole signals, one met the 
highest GPS threshold and two met the highest TreeScan threshold. The antifungal signals represent 
known AEs (e.g., liver conditions, allergic reactions, nausea) or likely confounding by indication (e.g., 
skin and subcutaneous tissue diagnoses) [32,44,45], Over 46,000 exposed days for terbinafine, 415,000 
exposed days for itraconazole, and 1.1 billion unexposed days were assessed. 
3.2. Pioglitazone and Rosiglitazone 
Of the 35 pioglitazone signals identified by either method, 15 met the highest GPS signaling 
threshold and 27 met the highest TreeScan threshold. For the 22 rosiglitazone signals, six met the 
highest GPS threshold and 15 met the highest TreeScan threshold (Table 3). Most of pioglitazone 
signals were in four body systems, including signals for Coronary Atherosclerosis and Other Heart 
Disease (MLCCS node 07.02.04), Congestive Heart Failure (07.02.11 and 07.02.11.01), and Peripheral 
and Visceral Atherosclerosis (07.04.01). Pioglitazone also had high threshold GPS signals for Nephritis, 
Nephrosis and Renal Sclerosis (10.01.01) and Chronic Renal Failure (10.01.03). Over 1.3 million 
exposed days for pioglitazone, 637,000 exposed days for rosiglitazone, and 1.1 billion unexposed days 
were assessed. 
The cardiovascular and renal signals are known AEs or likely due to confounding. For example, 
diabetes patients have a higher risk for renal impairment and, since diabetes medications such as 
metformin and glyburide are contraindicated for those with renal dysfunction, diabetes patients with 
renal impairment may have been channeled to pioglitazone and rosiglitazone. Both drugs also signaled 
strongly for chronic ulcer of the skin, and pioglitazone signaled for eye disorders, another likely 
example of confounding.  
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Table 2. Results for terbinafine and itraconazole. 
MLCCS Diagnosis 
Terbinafine Itraconazole 
Obs Exp O/E EBGM GPS Signal 
TreeScan 
p-value Obs Exp O/E EBGM GPS Signal 
TreeScan  
p-value 
05 Mental Disorders 0 0.6 0.0 1.3   . 0 0.1 0.0 1.4   . 
06 Diseases Of The Nervous System And Sense Organs 37 22.7 1.6 1.6   0.28 11 5.2 2.1 1.7   0.54 
07 Diseases Of The Circulatory System 51 44.4 1.1 1.2   . 21 10.2 2.1 1.7   0.13 
07.01 Hypertension 1 2.0 0.5 1.3 . 1 0.6 1.8 1.5 . 
07.02 Diseases Of The Heart 24 21.4 1.1 1.2 . 9 5.0 1.8 1.6 . 
07.02.01 Heart Valve Disorders 1 2.8 0.4 1.2 . 0 0.7 0.0 1.3 . 
07.02.03 Acute Myocardial Infarction 0 0.8 0.0 1.3 . 1 0.2 4.7 1.7 . 
07.02.04 Coronary Atherosclerosis And Other Heart Disease 3 3.4 0.9 1.3 . 1 0.9 1.1 1.5 . 
07.02.07 Other And Ill-Defined Heart Disease 3 1.0 3.1 1.7 . 3 0.2 12.3 3.9 0.09 
07.02.08 Conduction Disorders 1 0.5 1.9 1.5 . 1 0.1 7.9 1.8 . 
07.02.09 Cardiac Dysrhythmias 16 10.1 1.6 1.5 . 3 2.2 1.4 1.5 . 
07.03 Cerebrovascular Disease 4 2.9 1.4 1.5 . 2 0.7 2.9 1.6 . 
07.04 Diseases Of Arteries; Arterioles; And Capillaries 17 13.8 1.2 1.3 . 5 3.0 1.7 1.5 . 
07.05 Diseases Of Veins And Lymphatics 5 4.3 1.2 1.4   . 4 0.9 4.4 1.9   0.47 
09 Diseases Of The Digestive System 63 37.2 1.7 1.6   0.007 15 8.2 1.8 1.6   0.63 
09.03 Diseases Of Mouth; Excluding Dental 5 3.3 1.5 1.5 . 0 0.7 0.0 1.3 . 
09.04 Upper Gastrointestinal Disorders 8 7.2 1.1 1.3 . 5 1.5 3.3 1.8 0.53 
09.06 Lower Gastrointestinal Disorders 1 0.8 1.3 1.5 . 1 0.2 5.8 1.7 . 
09.07 Biliary Tract Disease 2 1.6 1.3 1.4 . 1 0.3 3.1 1.6 . 
09.08 Liver Disease 14 3.1 4.5 3.5 ** 0.00005 1 0.7 1.4 1.5 . 
09.08.02 Other Liver Diseases 14 3.1 4.5 3.37 ** 0.00005 1 0.7 1.4 1.5 . 
09.08.02.04 Other And Unspecified Liver Disorders 14 2.8 5.1 4.1 *** 0.00002 1 0.6 1.6 1.5 . 
09.09 Pancreatic Disorders (Not Diabetes) 2 0.3 5.9 1.9 . 1 0.1 15.0 2.0 . 
09.09.03 Other Pancreatic Disorders 2 0.1 36.9 4.2 0.06 1 0.0 69.3 2.2 . 
09.10 Gastrointestinal Hemorrhage 12 6.4 1.9 1.6 . 2 1.5 1.4 1.5 . 
09.12 Other Gastrointestinal Disorders 19 14.4 1.3 1.4   . 4 3.3 1.2 1.4   . 
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Table 2. Cont. 
MLCCS Diagnosis 
Terbinafine Itraconazole 
Obs Exp O/E EBGM GPS Signal 
TreeScan 
p-value Obs Exp O/E EBGM GPS Signal 
TreeScan  
p-value 
10 Diseases Of The Genitourinary System 29 23.5 1.2 1.3   . 1 5.5 0.2 0.4   . 
11 Complications Of Pregnancy; Childbirth; And The Puerperium 0 0.6 0.0 1.2   . 1 0.1 8.1 1.7   . 
12 Diseases Of The Skin And Subcutaneous Tissue 125 51.6 2.4 2.2 ** 0.00001 31 11.2 2.8 2.1 ** 0.00001 
12.01 Skin And Subcutaneous Tissue Infections 4 3.7 1.1 1.4 . 3 0.9 3.5 1.7 0.84 
12.02 Other Inflammatory Condition Of Skin 25 10.6 2.4 1.9 0.010 9 2.1 4.2 2.4 0.02 
12.03 Chronic Ulcer Of Skin 1 0.3 3.6 1.6 . 0 0.1 0.0 1.5 . 
12.04 Other Skin Disorders 95 37.0 2.6 2.3 ** 0.00001 19 8.1 2.3 1.8   0.05 
13 
Diseases Of The Musculoskeletal System And Connective 
Tissue 60 43.3 1.4 1.4   0.59 15 9.1 1.7 1.6   0.84 
13.01 
Infective Arthritis And Osteomyelitis (Except That Caused By 
TB Or STD 1 0.3 3.6 1.6 . 4 0.1 56.8 19.5 *** 0.00001 
13.08 Other Connective Tissue Disease 59 42.7 1.4 1.4   0.63 11 8.9 1.2 1.4   . 
16 Injury And Poisoning 2 0.8 2.6 1.6   . 0 0.2 0.0 1.4   . 
17 
Symptoms; Signs; And Ill-Defined Conditions And Factors 
Influencing Health 62 38.1 1.6 1.6   0.02 15 8.5 1.8 1.6   0.75 
17.01 Symptoms; Signs; And Ill-Defined Conditions 62 38.1 1.6 1.6 0.02 15 8.5 1.8 1.6 0.75 
17.01.01 Syncope 3 2.3 1.3 1.4 . 1 0.5 1.9 1.5 . 
17.01.06 Nausea And Vomiting 10 3.9 2.6 1.9 0.42 6 0.9 6.4 3.5 0.03 
17.01.07 Abdominal Pain 21 18.1 1.2 1.3 . 2 4.1 0.5 1.1 . 
17.01.08 Malaise And Fatigue 3 2.9 1.0 1.4 . 1 0.7 1.5 1.5 . 
17.01.09 Allergic Reactions 25 10.8 2.3 2.0   0.01 5 2.2 2.3 1.7   . 
MLCCS = Multi-level Clinical Classifications System; Obs = Observed; Exp = Expected; O/E = Observed/Expected; TreeScan p = multiple testing adjusted p-values, p > 0.90 is indicated 
with ‘.’; EBGM: empirical Bayesian geometric mean; *** GPS Signal at lower 90% CI bound ≥2; ** Signal at lower 95% CI bound >1.5; Table includes (1) all major disease category 
headings; (2) any disease categories that signaled for GPS or with a p-value ≤ 0.10; (3) any parents/grandparent of categories that signaled, and (4) any sibling of a disease category that 
signaled as long as there were observed events. We excluded any categories that were exactly the same as the parent. 
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Table 3. Results for pioglitazone and rosiglitazone. 
MLCCS Diagnosis 
Pioglitazone Rosiglitazone 
Obs Exp O/E EBGM 
GPS 
Signal 
TreeScan 
p-value Obs Exp O/E EBGM 
GPS 
Signal 
TreeScan  
p-value 
05 Mental Disorders 4 1.7 2.4 1.6   . 1 0.9 1.1 1.5   . 
06 Diseases Of The Nervous System And Sense Organs 197 90.7 2.2 2.1 ** 0.00001 75 45.1 1.7 1.6   0.003 
06.03 Paralysis 2 1.1 1.9 1.5 . 0 0.7 0.0 1.3 . 
06.04 Epilepsy; Convulsions 3 4.0 0.8 1.3 . 2 2.3 0.9 1.4 . 
06.05 Headache; Including Migraine 4 11.6 0.3 0.6 . 5 5.6 0.9 1.3 . 
06.06 Coma; Stupor; And Brain Damage 3 1.3 2.4 1.6 . 1 0.6 1.7 1.5 . 
06.07 Eye Disorders 185 72.9 2.5 2.4 *** 0.00001 67 35.9 1.9 1.8 0.00004 
06.07.01 Cataract 123 51.4 2.4 2.3 ** 0.00001 47 24.2 1.9 1.8 0.002 
06.07.03 Glaucoma 62 21.4 2.9 2.6 *** 0.00001 20 11.7 1.7 1.6   0.80 
07 Diseases Of The Circulatory System 378 177.7 2.1 2.1 ** 0.00001 186 94.8 2.0 1.9 ** 0.00001 
07.01 Hypertension 34 16.3 2.1 1.8 0.009 4 3.1 1.3 1.4 . 
07.01.02 Hypertension With Complications And Secondary Hypertension 34 16.3 2.1 1.9 0.009 4 3.1 1.3 1.4 . 
07.01.02.01 Hypertensive Heart And/Or Renal Disease 34 16.1 2.1 1.9 0.007 4 2.9 1.4 1.5 . 
07.02 Diseases Of The Heart 190 86.6 2.2 2.1 ** 0.00001 116 51.9 2.2 2.1 ** 0.00001 
07.02.01 Heart Valve Disorders 15 10.1 1.5 1.5 . 14 6.7 2.1 1.8 0.54 
07.02.02 
Peri-; Endo-; And Myocarditis; Cardiomyopathy (Except That 
Caused 6 2.2 2.7 1.8 0.89 4 1.1 3.8 1.9 0.80 
07.02.03 Acute Myocardial Infarction 12 4.0 3.0 2.0 0.08 5 1.8 2.8 1.8 . 
07.02.04 Coronary Atherosclerosis And Other Heart Disease 51 18.2 2.8 2.4 ** 0.00001 24 10.0 2.4 2.0 0.01 
07.02.04.00 Coronary Atherosclerosis And Other Heart Disease 11 3.6 3.1 2.1 0.10 3 1.6 1.8 1.6 . 
07.02.04.01 Angina Pectoris 16 6.3 2.5 2.0 0.08 8 3.1 2.6 1.8 0.66 
07.02.04.02 Unstable Angina (Intermediate Coronary Syndrome) 5 2.0 2.5 1.7 . 6 1.5 4.1 2.2 0.26 
07.02.04.03 Other Acute And Subacute Forms Of Ischemic Heart Disease 4 1.0 4.2 2.0 0.70 1 0.3 2.9 1.6 . 
07.02.04.05 Other Forms Of Chronic Heart Disease 15 5.2 2.9 2.1 0.03 6 3.4 1.8 1.6 . 
07.02.05 Nonspecific Chest Pain 2 1.8 1.1 1.4 . 2 1.6 1.3 1.5 . 
07.02.06 Pulmonary Heart Disease 1 1.2 0.8 1.4 . 4 0.8 5.0 2.2 0.48 
07.02.07 Other And Ill-Defined Heart Disease 5 5.2 1.0 1.3 . 11 3.1 3.5 2.2 0.03 
07.02.08 Conduction Disorders 2 2.2 0.9 1.4 . 4 1.4 2.8 1.7 . 
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Table 3. Cont. 
MLCCS Diagnosis 
Pioglitazone Rosiglitazone 
Obs Exp O/E EBGM GPS Signal
TreeScan 
p-value Obs Exp O/E EBGM GPS Signal 
TreeScan  
p-value 
07.02.09 Cardiac Dysrhythmias 48 33.3 1.4 1.5 0.63 28 21.9 1.3 1.3 . 
07.02.10 Cardiac Arrest And Ventricular Fibrillation 4 0.9 4.4 2.0 0.62 0 0.4 0.0 1.4 . 
07.02.11 Congestive Heart Failure; Nonhypertensive 44 7.3 6.0 5.9 *** 0.00001 20 3.2 6.3 6.0 *** 0.00001 
07.02.11.00 Congestive Heart Failure; Nonhypertensive 4 0.1 54.6 14.1 *** 0.00002 1 0.0 26.4 2.1 . 
07.02.11.01 Congestive Heart Failure 35 6.3 5.5 5.4 *** 0.00001 16 2.7 5.8 5.3 *** 0.00002 
07.02.11.02 Heart Failure 5 0.9 5.4 2.5 0.19 3 0.4 7.3 2.5 0.43 
07.03 Cerebrovascular Disease 40 15.1 2.6 2.2 ** 0.00001 13 7.1 1.8 1.6 . 
07.03.01 Acute Cerebrovascular Disease 14 5.9 2.4 1.9 0.27 1 2.3 0.4 1.2 . 
07.03.02 Occlusion Or Stenosis Of Precerebral Arteries 7 2.8 2.5 1.8 0.86 8 1.3 6.1 4.1 ** 0.00472 
07.03.03 Other And Ill-Defined Cerebrovascular Disease 3 1.6 1.9 1.6 . 1 1.2 0.8 1.4 . 
07.03.04 Transient Cerebral Ischemia 14 3.9 3.6 2.4 0.006 2 1.6 1.3 1.5 . 
07.03.05 Late Effects Of Cerebrovascular Disease 2 0.9 2.2 1.6 . 1 0.7 1.5 1.5 . 
07.04 Diseases Of Arteries; Arterioles; And Capillaries 81 44.8 1.8 1.7 0.00002 41 25.7 1.6 1.6 0.28149 
07.04.01 Peripheral And Visceral Atherosclerosis 33 7.6 4.4 4.1 *** 0.00001 18 3.8 4.7 4.0 *** 0.00002 
07.04.01.01 Atherosclerosis Of Arteries Of Extremities 9 1.6 5.5 3.6 ** 0.005 3 0.7 4.2 1.9 . 
07.04.01.02 Peripheral Vascular Disease Unspecified 21 4.9 4.3 3.5 *** 0.00001 11 2.4 4.7 3.1 ** 0.0023 
07.04.01.03 Other Peripheral And Visceral Atherosclerosis 3 1.0 3.0 1.7 . 4 0.8 5.2 2.2 0.43304 
07.04.02 Aortic; Peripheral; And Visceral Artery Aneurysms 1 1.9 0.5 1.3 . 3 1.1 2.7 1.7 . 
07.04.03 Aortic And Peripheral Arterial Embolism Or Thrombosis 5 0.9 5.3 2.5 0.20 2 0.4 4.6 1.8 . 
07.04.04 Other Circulatory Disease 42 34.4 1.2 1.3 . 18 20.4 0.9 1.1 . 
07.04.04.01 Hypotension 8 1.8 4.6 2.6 0.04 0 0.7 0.0 1.4 . 
07.04.04.02 Other And Unspecified Circulatory Disease 34 32.7 1.0 1.1 . 18 19.6 0.9 1.1 . 
07.05 Diseases Of Veins And Lymphatics 33 14.9 2.2 1.9 0.004 12 6.9 1.7 1.6 . 
07.05.01 Phlebitis; Thrombophlebitis And Thromboembolism 9 4.2 2.1 1.7 . 8 2.5 3.2 2.0 0.27 
07.05.02 Varicose Veins Of Lower Extremity 5 5.8 0.9 1.2 . 1 2.7 0.4 1.2 . 
07.05.04 Other Diseases Of Veins And Lymphatics 19 5.0 3.8 2.9 ** 0.00002 3 1.7 1.7 1.5   . 
09 Diseases Of The Digestive System 131 116.4 1.1 1.2   . 80 62.0 1.3 1.3   0.79 
10 Diseases Of The Genitourinary System 186 75.0 2.5 2.3 *** 0.00001 96 45.4 2.1 2.0 ** 0.00001 
10.01 Diseases Of The Urinary System 167 63.7 2.6 2.5 *** 0.00001 86 35.5 2.4 2.2 ** 0.00001 
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Table 3. Cont. 
MLCCS Diagnosis 
Pioglitazone Rosiglitazone 
Obs Exp O/E EBGM
GPS 
Signal 
TreeScan 
p-value Obs Exp O/E EBGM 
GPS 
Signal 
TreeScan  
p-value 
10.01.01 Nephritis; Nephrosis; Renal Sclerosis 28 1.2 24.3 21.0 *** 0.00001 6 0.7 8.7 5.7 ** 0.005 
10.01.02 Acute And Unspecified Renal Failure 3 1.2 2.6 1.7 . 1 0.6 1.6 1.5 . 
10.01.03 Chronic Renal Failure 14 1.6 9.0 8.3 *** 0.00001 7 0.7 10.1 7.8 *** 0.0001 
10.01.04 Urinary Tract Infections 6 1.3 4.7 2.4 0.15 2 0.6 3.4 1.7 . 
10.01.05 Calculus Of Urinary Tract 6 8.6 0.7 1.1 . 3 4.2 0.7 1.2 . 
10.01.06 Other Diseases Of Kidney And Ureters 30 6.2 4.8 4.7 *** 0.00001 14 3.4 4.1 2.9 ** 0.0004 
10.01.06.02 Other And Unspecified Diseases Of Kidney And Ureters 30 5.5 5.5 5.3 *** 0.00001 14 3.0 4.7 3.6 ** 0.00004 
10.01.07 Other Diseases Of Bladder And Urethra 0 1.0 0.0 1.3 . 1 0.6 1.8 1.5 . 
10.01.08 Genitourinary Symptoms And Ill-Defined Conditions 80 42.8 1.9 1.8 0.00002 52 24.7 2.1 1.9 ** 0.00002 
10.01.08.01 Hematuria 13 11.9 1.1 1.3 . 14 7.5 1.9 1.7 0.86 
10.01.08.02 Retention Of Urine 3 2.8 1.1 1.4 . 1 1.3 0.7 1.4 . 
10.01.08.03 Other And Unspecified Genitourinary Symptoms 64 28.1 2.3 2.1 ** 0.00001 37 15.9 2.3 2.1 ** 0.00007 
10.03 Diseases Of Female Genital Organs 19 11.2 1.7 1.6   0.88 10 9.9 1.0 1.3   . 
11 Complications Of Pregnancy; Childbirth; And The Puerperium 0 0.5 0.0 1.3   . 0 0.3 0.0 1.3   . 
12 Diseases Of The Skin And Subcutaneous Tissue 205 166.6 1.2 1.3   0.23 78 70.5 1.1 1.2   . 
12.01 Skin And Subcutaneous Tissue Infections 17 7.9 2.2 1.7 0.26 9 4.2 2.1 1.6 . 
12.02 Other Inflammatory Condition Of Skin 41 33.8 1.2 1.3 . 15 13.1 1.1 1.3 . 
12.03 Chronic Ulcer Of Skin 13 1.1 11.8 10.7 *** 0.00001 9 0.4 21.2 16.4 *** 0.00001 
12.03.02 Chronic Ulcer Of Leg Or Foot 13 1.1 11.8 10.4 *** 0.00001 9 0.4 21.2 15.1 *** 0.00001 
12.04 Other Skin Disorders 134 123.8 1.1 1.1   . 45 52.7 0.9 1.0   . 
13 Diseases Of The Musculoskeletal System And Connective Tissue 187 131.8 1.4 1.4   0.00008 84 57.7 1.5 1.5   0.07 
13.01 Infective Arthritis And Osteomyelitis (Except That Caused By TB Or STD 2 1.0 2.0 1.5 . 1 0.6 1.6 1.5 . 
13.07 Systemic Lupus Erythematosus And Connective Tissue Disorders 1 1.1 0.9 1.4 . 2 0.7 2.9 1.6 . 
13.08 Other Connective Tissue Disease 184 129.6 1.4 1.4   0.0001 81 56.4 1.4 1.4   0.13 
16 Injury And Poisoning 2 1.8 1.1 1.4   . 1 0.9 1.1 1.4   . 
17 Symptoms; Signs; And Ill-Defined Conditions And Factors Influencing Health 128 106.8 1.2 1.2   . 57 50.4 1.1 1.2   . 
MLCCS = Multi-level Clinical Classifications System; Obs = Observed; Exp = Expected; O/E = Observed/Expected; TreeScan p = multiple testing adjusted p-values, p > 0.90 is indicated 
with ‘.’; EBGM: empirical Bayesian geometric mean; *** GPS Signal at lower 90% CI bound ≥2; **Signal at lower 95% CI bound >1.5; Table includes (1) all major disease category 
headings; (2) any disease categories that signaled for GPS or with a p-value ≤ 0.10; (3) any parents/grandparent of categories that signaled, and (4) any sibling of a disease category that 
signaled as long as there were observed events. We excluded any categories that were exactly the same as the parent. 
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3.3. Overall Signaling Comparison  
Table 4 presents all 71 signals. TreeScan identified 71 signals, 49 at the highest threshold  
(p ≤ 0.001) and 22 at medium threshold (0.001< p < 0.05). GPS identified 48 signals; all high 
threshold GPS signals were also high threshold TreeScan signals, and 84% (21/25) of the moderate 
threshold GPS signals were high TreeScan signals. There were five high threshold TreeScan signals 
that did not signal for GPS, all had low O/E ratios (1.4 to 1.9) and large observed counts (67 to 187).  
Table 4. Comparison of all GPS and TreeScan signals across the four drugs studied by threshold. 
Tree-Based Scan Statistic (TreeScan) Signal Thresholds 
GPS Signal Thresholds p ≤ 0.001 0.001< p ≤ 0.05 Total (%) 
High 23 0 23 (32) 
Medium 21 4 25 (35) 
No signal 5 18 23 (32) 
TOTAL 49 22 71 
GPS Thresholds  
Medium: lower 95% CI bound ≥1.5 
High: lower 90% CI bound >2.0 
Thresholds are mutually exclusive 
Note: Data are no. (% of all signals). GPS: Gamma Poisson Shrinker. 
4. Discussion 
Electronic healthcare databases hold promise for pharmacovigilance because they address common 
shortcomings inherent to spontaneous reporting systems, offer large sample sizes and the potential to 
study subgroups, and include longitudinal medical information for a defined population. This is the 
first study to apply the GPS to population-based observational data in a multi-site environment for 
assessment of non-prespecified outcomes. Prior studies have implemented GPS in similar environments 
but have focused on pre-specified drug-event pairs.  
We identified 71 signals across four drug products. Of the 48 GPS signals identified, 23 (48%) 
signaled at the highest threshold. We did not formally evaluate each signal for clinical plausibility or 
prior knowledge of association, or prioritize them for refinement. All GPS signals were either known 
associations or could be reasonably attributed to confounding. We counted as unique every signal at 
each level of the hierarchical tree, an approach that overestimates the number of signals that would 
require refinement under a real-world implementation. For example, we counted signals for Diseases 
of the Nervous System and Sense Organs (06), Eye Disorders (06.07), Cataracts (06.07.01), and 
Glaucoma (06.07.03) as four distinct signals, although the higher-level signals (06 and 06.07) were 
almost entirely made up of the two lower-level signals and would not require four distinct signal 
refinement activities.  
The GPS and TreeScan results were similar with respect to the clinical areas that signaled, although 
findings varied by signaling threshold. In the few cases that GPS did not signal and TreeScan signaled 
at highest threshold, observed counts were high and O/E was low. This is expected behavior based on 
the nature of the two methods. 
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We note that using observational data for signal detection requires complex and often subjective 
analytic specifications, often unstated, that can directly affect the interpretation of the findings. Our 
implementation applied common epidemiologic approaches such as allowing individuals to contribute 
exposed and unexposed person time, and most importantly, involved identification of non-specified 
incident outcomes. The pilot was conducted using a fully distributed approach that did not require 
sharing of person-level protected health data but allowed identical definitions and analyses to be 
performed at each data partner.  
Implementation required specifications such as the baseline period, the allowable enrollment gap, 
the definition of contributed, exposed, and unexposed time, the creation of treatment episodes, 
allowable treatment gaps, right censoring decisions, and incident outcome definitions. A longer 
baseline period could reduce confounding by indication by identifying more patients with prevalent 
comorbid conditions, but would reduce overall cohort size due to lack of complete baseline. The 
incident outcome also can be defined several ways taking into account baseline period, care setting 
(inpatient versus outpatient), and diagnosis coding hierarchy. By excluding diagnoses unlikely to be 
associated with an acute outcome we eliminated the possibility of identifying the excluded diagnoses 
as outcomes. Our exclusion of injury and poisoning codes is debatable; those codes could be valuable 
in identifying those risks, but there is some uncertainty about how well those codes reflect adverse 
events versus misuse of safe medications (e.g., overdose). Regardless, they could be added in future 
implementations, especially in combination with loosening our simplifying restriction that allowed 
only one incident event per person. Finally, we compared exposed to unexposed time, controlling for 
age group, sex, and health plan. Others options for confounding adjustment include using an exposed 
comparison cohort, narrower age stratifications, and matching or disease severity stratification.  
Further, we note that we did not identify a set of expected signals that we hoped to find (e.g., 
expected adverse drug events) or avoid (e.g., confounded signals). Rather, since others have identified 
GPS as a potentially valuable tool for signal detection, our goal was to investigate the feasibility of 
implementing GPS and TreeScan in a real-world large-scale data mining application using longitudinal 
electronic health data without limiting the analysis to pre-specified relationships. We reviewed the 
product label, medical literature, and consulted clinical experts (co-authors and others) to informally 
assess whether identified signals were known or reasonably expected due to confounding. In our view 
there is no clear and well defined list of all known adverse drug events. Most drug labels have 
extensive adverse event list, but there is no conclusive evidence that all these “adverse events” are 
caused by the drug. For black box warnings there is usually strong evidence, but most known adverse 
events do not generate a black box warning. Developing a comprehensive list of all possible adverse 
events was beyond the scope of the paper and inconsistent with our primary aim to assess 
implementation in a real world setting.  
There is no “correct” decision regarding signaling thresholds, only generally understood trade-offs 
between identifying more or fewer signals and the resulting changes in numbers of signals needing 
refinement. The ability to interpret the signal detection findings within the larger pharmacovigilance 
framework, the ability of the findings to inform decision-making, and effort needed to evaluate them 
are important factors in whether or not a surveillance approach is viable. For instance, a viable 
approach will generate signals with enough informational value that they can be quickly adjudicated as 
Pharmaceutics 2013, 5 195 
 
likely due to confounding, known, expected, or otherwise uninteresting versus those that require 
further evaluation and refinement.  
We have shown that the GPS method can be successfully applied to population-based health plan 
data and that it performs adequately, with the ability to detect known adverse events. Although the 
GPS always shrinks the O/E estimate to some value to reduce variability, it is not always the case that 
the O/E shrinks towards 1.0 [38]. We observed shrinkage towards approximately 1.5. This property 
could be seen as less than desirable. It reflects that across all the outcome events under study, there is 
an excess number of events compared to the expected. Thus, the O/E is shrunk towards some average 
O/E taken over all outcomes. The fact that this is more than 1.0 could be because the drug causes a 
whole range of adverse events, or more likely, that the drug is taken by a generally sicker or more frail 
population that experiences a whole range of comorbidities. Prior implementations of GPS in 
longitudinal data did not report this finding or any metrics regarding the prior distributions. This 
finding emphasizes the need for research with empirical Bayesian approaches to report details of the 
prior distribution so that it is clear to which value shrinkage occurs, and in general the importance of 
transparency of reported findings, around for example, signaling thresholds and the need to consider 
alternative implementation approaches such as the use of zero-inflated Poisson to account for the many 
empty cells and underlying variability. More research regarding the appropriate implementation 
strategy for GPS using longitudinal data and signaling thresholds and strategies for multi-level testing 
are also needed, including the potential to adjust thresholds and approaches based on the specific 
surveillance target(s) and perhaps observed prior distributions. 
Compared with TreeScan, there are both strengths and weaknesses to GPS, and it may be ideal to 
employ both methods simultaneously, using the combined results to better strengthen, refute, and 
understand signals. A strength of the GPS method is the Bayesian probability intervals; shrinkage of 
the point estimates towards the population average of O/E is a possible strength, although care must be 
taken to insure “shrinkage” towards values over unity does not introduce signals. We suggest future 
implementations carefully assess the GPS parameter sets to understand the distribution of O/E in the 
underlying population. A major strength of the TreeScan is the formal adjustment for multiple testing 
and the ability to analyze different levels of disease granularity in a single combined analysis.  
Signal detection is one step in the continuum of medical product safety surveillance. Approaches 
that generate statistical signals difficult to refine are of little practical use [46]—potentially creating an 
unfortunate situation in which new signal detection methods generate more heat than light. Therefore, 
it is critical that a robust medical product safety surveillance system have efficient mechanisms—such 
as those proposed by diverse stakeholders including the governmental agencies, academia and the 
pharmaceutical industry to quickly prioritize, refine and evaluate and act on signals. Examples of novel 
approaches to surveillance and signal management include the work of the US FDA Sentinel  
System [31,47,48] the WHO Collaborating Centre for International Drug Monitoring [49], the Asian 
Pharmacoepidemiology Network [50], and the European Network of Centres for Pharmacoepidemiology 
and Pharmacovigilance [51], and are being tested in multiple major international initiatives [52–54].  
  
Pharmaceutics 2013, 5 196 
 
Acknowledgments 
This work was funded by Pfizer Inc. (JSB, FZ, ID, TRA) and the Agency for Healthcare Research 
and Quality (JSB, ID, MK, KAC, RLD, SEA, DB, MJG, LH, PP, MAR, DR, DS, RP), through a grant 
to the HMO Research Network Center for Education and Research on Therapeutics (CERT), grant 
number U18 HS 010391. KP, AB, and RR are employees of Pfizer Inc. 
We are indebted to the statistical programmers at each of the sites for their work in extracting the 
study data and testing the programming algorithms, to Kimberly Lane and the HMO Research 
Network CERT Data Coordinating Center for their help in overseeing the study.  
Conflicts of Interest 
The authors declare no conflicts of interest. 
References 
1. Bate, A.; Evans, S.J. Quantitative signal detection using spontaneous ADR reporting. 
Pharmacoepidemiol. Drug Saf. 2009, 18, 427–436. 
2. Curtis, J.R.; Cheng, H.; Delzell, E.; Fram, D.; Kilgore, M.; Saag, K.; Yun, H.; Dumouchel, W. 
Adaptation of Bayesian data mining algorithms to longitudinal claims data: Coxib safety as an 
example. Med. Care 2008, 46, 969–975. 
3. Schuemie, M.J. Methods for drug safety signal detection in longitudinal observational databases: 
LGPS and LEOPARD. Pharmacoepidemiol. Drug Saf. 2011, 20, 292–299. 
4. Norén, G.N.; Bate, A.; Hopstadius, J.; Star, K.; Edwards, I.R. In Temporal Pattern Discovery for 
Treands and Transient Effects: Its Application to Patient Records, Proceedings of The 14th ACM 
SIGKDD International Conference on Knowledge Discovery and Data Mining, Las Vegas, NV, 
USA, August 24–27, 2008; pp. 963–971. 
5. Brown, J.S.; Petronis, K.; Bate, A.; Zhang, F.; Dashevsky, I.; Kulldorff, M.; Avery, T.A.;  
Davis, R.L.; Andrade, S.E.; Dublin, S.; et al. Comparing Two Methods for Detecting Adverse 
Event Signals in Observational Data: Empirical Bayes Gamma Poisson Shrinker and Tree-Based 
Scan Statistic, Proceedings of The 27th International Conference on Pharmacoepidemiology and 
Therapeutic Risk Management, The International Society for Pharmacoepidemiology Chicago, 
Chicago, IL, USA, August 14–17, 2011; p. Abstract 575. 
6. Kulldorff, M.; Dashevsky, I.; Avery, T.A.; Chan, K.A.; Davis, R.L.; Graham, D.; Platt, R.; 
Andrade, S.E.; Boudreau, D.; Gunter, M.J.; et al. In Drug Safety Data Mining with a Tree-Based 
Scan Statistic, Proceedings of 26th International Conference on Pharmacoepidemiology and 
Therapeutic Risk Management, Brighton, England, UK, 2010. 
7. Park, M.Y.; Yoon, D.; Lee, K.; Kang, S.Y.; Park, I.; Lee, S.H.; Kim, W.; Kam, H.J.; Lee, Y.H.; 
Kim, J.H.; et al. A novel algorithm for detection of adverse drug reaction signals using a hospital 
electronic medical record database. Pharmacoepidemiol. Drug Saf. 2011, 20, 598–607. 
8. Jin, H.W.; Chen, J.; He, H.; Williams, G.J.; Kelman, C.; O’Keefe, C.M. Mining unexpected 
temporal associations: Applications in detecting adverse drug reactions. IEEE Trans. Inf. Technol. 
Biomed. 2008, 12, 488–500. 
Pharmaceutics 2013, 5 197 
 
9. Walker, A.M. Signal detection for vaccine side effects that have not been specified in advance. 
Pharmacoepidemiol. Drug Saf. 2010, 19, 311–317. 
10. Harpaz, R.; DuMouchel, W.; Shah, N.H.; Madigan, D.; Ryan, P.; Friedman, C. Novel data-mining 
methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 2012, 91, 
1010–1021. 
11. Zorych, I.; Madigan, D.; Ryan, P.; Bate, A. Disproportionality methods for pharmacovigilance in 
longitudinal observational databases. Stat. Methods Med. Res. 2011, 22, 39–56. 
12. Norén, G.N.; Hopstadius, J.; Bate, A.; Star, K.; Edwards, I.R. Temporal pattern discovery in 
longitudinal electronic patient records. Data Min. Knowl. Discov. 2010, 20, 361–387. 
13. Schuemie, M.J.; Coloma, P.M.; Straatman, H.; Herings, R.M.; Trifiro, G.; Matthews, J.N.;  
Prieto-Merino, D.; Molokhia, M.; Pedersen, L.; Gini, R.; et al. Using electronic health care 
records for drug safety signal detection: a comparative evaluation of statistical methods. Med. 
Care 2012, 50, 890–897. 
14. Norén, G.N.; Hopstadius, J.; Bate, A.; Edwards, I.R. Safety surveillance of longitudinal databases: 
Results on real-world data. Pharmacoepidemiol. Drug Saf. 2012, 21, 673–675. 
15. Noren, G.N.; Hopstadius, J.; Bate, A.; Edwards, I.R. Safety surveillance of longitudinal databases: 
Methodological considerations. Pharmacoepidemiol. Drug Saf. 2011, 20, 714–717. 
16. Schuemie, M.J. Safety surveillance of longitudinal databases: further methodological 
considerations. Pharmacoepidemiol. Drug Saf. 2012, 21, 670–672. 
17. Bate, A.; Brown, E.G.; Goldman, S.A.; Hauben, M. Terminological challenges in safety 
surveillance. Drug Saf. 2012, 35, 79–84. 
18. Ryan, P.B.; Madigan, D.; Stang, P.E.; Overhage, J.M.; Racoosin, J.A.; Hartzema, A.G. Empirical 
assessment of methods for risk identification in healthcare data: Results from the experiments of 
the Observational Medical Outcomes Partnership. Stat. Med. 2012, 31, 4401–4415. 
19. Vaccine Safety Monitoring—Adverse Events. Available online: http://www.mini-sentinel.org/ 
methods/methods_development/details.aspx?ID=1028 (accessed on 15 August 2012). 
20. Yih, W.K.; Kulldorff, M.; Fireman, B.H.; Shui, I.M.; Lewis, E.M.; Klein, N.P.; Baggs, J.; 
Weintraub, E.S.; Belongia, E.A.; Naleway, A.; et al. Active surveillance for adverse events: The 
experience of the Vaccine Safety Datalink project. Pediatrics 2011, 127, S54–S64. 
21. Platt, R.; Davis, R.; Finkelstein, J.; Go, A.S.; Gurwitz, J.H.; Roblin, D.; Soumerai, S.;  
Ross-Degnan, D.; Andrade, S.; Goodman, M.J.; et al. Multicenter epidemiologic and health 
services research on therapeutics in the HMO Research Network Center for Education and 
Research on Therapeutics. Pharmacoepidemiol. Drug Saf. 2001, 10, 373–377. 
22. Platt, R.; Andrade, S.E.; Davis, R.L.; Destefano, F.; Finkelstein, J.A.; Goodman, M.J.;  
Gurwitz, J.Y.; Go, A.S.; Martinson, B.C.; Raebel, M.A.; et al. Pharmacovigilance in the HMO 
Research Network. In Pharmacovigilance; Mann, R.D., Andrews, E.B., Eds.; Wiley: New York, 
NY, USA, 2002; pp. 392–398. 
23. Raebel, M.A.; Lyons, E.E.; Andrade, S.E.; Chan, K.A.; Chester, E.A.; Davis, R.L.; Ellis, J.L.; 
Feldstein, A.; Gunter, M.J.; Lafata, J.E.; et al. Laboratory monitoring of drugs at initiation of 
therapy in ambulatory care. J. Gen. Intern. Med. 2005, 20, 1120–1126. 
Pharmaceutics 2013, 5 198 
 
24. Raebel, M.A.; McClure, D.L.; Simon, S.R.; Chan, K.A.; Feldstein, A.; Andrade, S.E.; Lafata, J.E.; 
Roblin, D.; Davis, R.L.; Gunter, M.J.; et al. Laboratory monitoring of potassium and creatinine in 
ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor 
blockers. Pharmacoepidemiol. Drug Saf. 2007, 16, 55–64. 
25. Simon, S.R.; Andrade, S.E.; Ellis, J.L.; Nelson, W.W.; Gurwitz, J.H.; Lafata, J.E.; Davis, R.L.; 
Feldstein, A.; Raebel, M.A. Baseline laboratory monitoring of cardiovascular medications in 
elderly health maintenance organization enrollees. J. Am. Geriatr. Soc. 2005, 53, 2165–2169. 
26. Simon, S.R.; Chan, K.A.; Soumerai, S.B.; Wagner, A.K.; Andrade, S.E.; Feldstein, A.C.;  
Lafata, J.E.; Davis, R.L.; Gurwitz, J.H. Potentially inappropriate medication use by elderly 
persons in U.S. Health Maintenance Organizations, 2000–2001. J. Am. Geriatr. Soc. 2005, 53, 
227–232. 
27. Wagner, A.K.; Chan, K.A.; Dashevsky, I.; Raebel, M.A.; Andrade, S.E.; Lafata, J.E.; Davis, R.L.; 
Gurwitz, J.H.; Soumerai, S.B.; Platt, R. FDA drug prescribing warnings: is the black box half 
empty or half full? Pharmacoepidemiol. Drug Saf. 2006, 15, 369–386. 
28. Chan, J.; Hui, R.L.; Levin, E. Differential association between statin exposure and elevated levels 
of creatine kinase. Ann. Pharmacother. 2005, 39, 1611–1616. 
29. Velentgas, P.; Bohn, R.L.; Brown, J.S.; Chan, K.A.; Gladowski, P.; Holick, C.N.; Kramer, J.M.; 
Nakasato, C.; Spettell, C.M.; Walker, A.M.; et al. A distributed research network model for  
post-marketing safety studies: The Meningococcal Vaccine Study. Pharmacoepidemiol. Drug Saf. 
2008, 17, 1226–1234. 
30. Brown, J.; Moore, K.; Braun, M.; Ziyadeh, N.; Chan, K.; Lee, G.; Kulldorff, M.; Walker, A.; 
Platt, R. Active influenza vaccine safety surveillance: Potential within a healthcare claims 
environment. Med. Care 2009, 47, 1251–1257. 
31. Behrman, R.E.; Benner, J.S.; Brown, J.S.; McClellan, M.; Woodcock, J.; Platt, R. Developing the 
Sentinel System—A national resource for evidence development. N. Engl. J. Med. 2011, 364, 
498–499. 
32. Perveze, Z.; Johnson, M.W.; Rubin, R.A.; Sellers, M.; Zayas, C.; Jones, J.L.; Cross, R.; Thomas, K.; 
Butler, B.; Shrestha, R. Terbinafine-induced hepatic failure requiring liver transplantation. Liver 
Transpl. 2007, 13, 162–164. 
33. Lou, H.Y.; Fang, C.L.; Fang, S.U.; Tiong, C.; Cheng, Y.C.; Chang, C.C. Hepatic failure related to 
itraconazole use successfully treated by corticosteroids. Hepat. Mon. 2011, 11, 843–846. 
34. Nikkels, A.F.; Nikkels-Tassoudji, N.; Pierard, G.E. Oral antifungal-exacerbated inflammatory 
flare-up reactions of dermatomycosis: Case reports and review of the literature. Am. J. Clin. 
Dermatol. 2006, 7, 327–331. 
35. Cançado, G.G.; Fujiwara, R.T.; Freitas, P.A.; Correa-Oliveira, R.; Bethony, J.M. Acute 
generalized exanthematous pustulosis induced by itraconazole: an immunological approach.  
Clin. Exp. Dermatol. 2009, 34, e709–e711. 
36. Elixhauser, A.; Steiner, C.; Palmer, L. Clinical Classifications Software (CCS), 2009. Agency for 
Healthcare Research and Quality. Available online: http://www.hcup-us.ahrq.gov/toolssoftware/ 
ccs/ccs.jsp (accessed on 15 August 2012). 
37. DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA 
spontaneous reporting system. Am. Stat. 1999, 53, 177–190. 
Pharmaceutics 2013, 5 199 
 
38. Fram, D.; Almenoff, J.S.; Dumouchel, W. Empirical Bayesian Data Mining for Discovering 
Patterns in Post-Marketing Drug Safety. In Proceedings of the Ninth ACM SIGKDD International 
Conference on Knowledge Discovery and Data Mining, Washington DC, USA, August 24−27, 
2003; pp. 359–368. 
39. Banks, D.; Woo, E.J.; Burwen, D.R.; Perucci, P.; Braun, M.M.; Ball, R. Comparing data mining 
methods on the VAERS database. Pharmacoepidemiol. Drug Saf. 2005, 14, 601–609. 
40. Almenoff, J.S.; DuMouchel, W.; Kindman, L.A.; Yang, X.; Fram, D. Disproportionality analysis 
using empirical Bayes data mining: A tool for the evaluation of drug interactions in the  
post-marketing setting. Pharmacoepidemiol. Drug Saf. 2003, 12, 517–521. 
41. Szarfman, A.; Machado, S.G.; O’Neill, R.T. Use of screening algorithms and computer systems to 
efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s 
spontaneous reports database. Drug Saf. 2002, 25, 381–392. 
42. Kulldorff, M.; Dashevsky, I.; Avery, T.; Chan, A.; Davis, R.; Graham, D.; Platt, R.; Andrade, S.; 
Boudreau, D.; Dublin, S.; et al. Drug Safety Data Mining with a Tree-Based Scan Statistic. 
Pharmacoepidemiol. Drug Saf. 2013, in press. 
43. Kulldorff, M.; Fang, Z.; Walsh, S.J. A tree-based scan statistic for database disease surveillance. 
Biometrics 2003, 59, 323–331. 
44. Tuccori, M.; Bresci, F.; Guidi, B.; Blandizzi, C.; Del Tacca, M.; Di Paolo, M. Fatal hepatitis after 
long-term pulse itraconazole treatment for onychomycosis. Ann. Pharmacother. 2008, 42,  
1112–1117. 
45. Kohli, R.; Hadley, S. Fungal arthritis and osteomyelitis. Infect. Dis. Clin. North Am. 2005, 19, 
831–851. 
46. Avorn, J.; Schneeweiss, S. Managing drug-risk information—What to do with all those new 
numbers. N. Engl. J. Med. 2009, 361, 647–649. 
47. Robb, M.A.; Racoosin, J.A.; Sherman, R.E.; Gross, T.P.; Ball, R.; Reichman, M.E.; Midthun, K.; 
Woodcock, J. The US Food and Drug Administration’s Sentinel Initiative: Expanding the 
horizons of medical product safety. Pharmacoepidemiol. Drug Saf. 2012, 21, 9–11. 
48. Platt, R.; Carnahan, R.M.; Brown, J.S.; Chrischilles, E.; Curtis, L.H.; Hennessy, S.; Nelson, J.C.; 
Racoosin, J.A.; Robb, M.; Schneeweiss, S.; et al. The U.S. Food and Drug Administration’s  
Mini-Sentinel program: Status and direction. Pharmacoepidemiol. Drug Saf. 2012, 21, 1–8. 
49. Olsson, S. The role of the WHO programme on International Drug Monitoring in coordinating 
worldwide drug safety efforts. Drug Saf. 1998, 19, 1–10. 
50. Asian Pharmacoepidemiology Network. Available online: http://aspennet.asia/index.html 
(accessed on 21 November 2012). 
51. Blake, K.V.; Devries, C.S.; Arlett, P.; Kurz, X.; Fitt, H. Increasing scientific standards, 
independence and transparency in post-authorisation studies: The role of the European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol. Drug Saf. 
2012, 21, 690–696. 
52. Stang, P.E.; Ryan, P.B.; Racoosin, J.A.; Overhage, J.M.; Hartzema, A.G.; Reich, C.; Welebob, E.; 
Scarnecchia, T.; Woodcock, J. Advancing the science for active surveillance: Rationale and 
design for the Observational Medical Outcomes Partnership. Ann. Intern. Med. 2010, 153, 600–606. 
Pharmaceutics 2013, 5 200 
 
53. Coloma, P.M.; Schuemie, M.J.; Trifiro, G.; Gini, R.; Herings, R.; Hippisley-Cox, J.; Mazzaglia, 
G.; Giaquinto, C.; Corrao, G.; Pedersen, L.; et al. Combining electronic healthcare databases in 
Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. 
Pharmacoepidemiol. Drug Saf. 2011, 20, 1–11. 
54. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium 
IMI-PROTECT. Available online: http://www.imi-protect.eu/ (accessed on 21 November 2012). 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
